Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Phase 1/2 Recruiting 110 enrolled Auricula Biosciences Inc. Simbec-Orion Group · collab

NaSequentialOpen-labelTreatment

Summary

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

Timeline

Start: 2025-07-28
Primary completion: 2028-01
Completion: 2028-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	WEF-001	Unknown	0.3 mg/m2	Intravenous

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Summary

Timeline

Drugs

Indications